The Michael J. Fox Foundation will pay USD 6.5 million for Nightingale Health to analyse 60,000 UK Biobank samples for neurodegeneration markers. The company disclosed the agreement as inside information on 30 September. A day later, Nightingale published an annual report setting a revenue target of at least EUR 10 million for the current financial year.

The work will use Alamar Biosciences' NULISAseq™ Neuro 220 Panel, which is designed for neurodegeneration and other brain health conditions. At the Foundation's direction, the dataset goes to UK Biobank and opens to the wider research community in 2027. The aim is to find blood markers that change years before the symptoms of Alzheimer's and Parkinson's appear.

CEO and founder Teemu Suna said the company believes the deal will produce the world's largest brain health-focused proteomics study on a single research cohort.

The contract puts Nightingale's move into proteomics to work

The annual report says Nightingale expanded its offering into proteomics in response to growing interest in multiomics, strengthening its position in the research market. The step came through its November 2025 partnership with Alamar.

The report describes research as a separate business with its own customers and products. It is also where much of the evidence for Nightingale's healthcare business comes from, including measurements of all roughly 500,000 UK Biobank participants. The largest research agreements the report lists for the past financial year were with Aalborg University, at about EUR 2.4 million, and the Moli-sani study, at about EUR 0.7 million.

Revenue follows the samples, and the first read comes in March

Nightingale's revenue for the financial year ended June 2026 was EUR 5.50 million, up from EUR 4.69 million. That fell short of the more than 50% growth the company had targeted. In June, Nightingale warned that a EUR 2.4 million project announced in September 2025 had been delayed for reasons outside its control. As a result, about EUR 2 million of revenue moves into the current financial year. Suna called it "timing, not lost business".

The company recognises revenue over time as samples are analysed. It collects advance payments for most of its services, and the gap between payment and analysis is typically three to six months. The release gives no timeline for analysing the 60,000 samples.

The company expects its liquid funds of EUR 36.8 million to last until the end of the 2027/2028 financial year. The half-year report on 9 March 2027 will be the first chance to see how much of the delayed project and the Fox Foundation contract has turned into revenue towards the EUR 10 million target.

|

|

Business

Nightingale Health's USD 6.5 million brain health deal lands as it targets EUR 10 million in revenue

Nightingale Health's USD 6.5 million brain health deal lands as it targets EUR 10 million in revenue

·

5 min read

Explore and follow profiles from this article to get timely updates:

Credit: Nightingale Health

Credit: Nightingale Health

The Michael J. Fox Foundation will pay USD 6.5 million for Nightingale Health to analyse 60,000 UK Biobank samples for neurodegeneration markers. The company disclosed the agreement as inside information on 30 September. A day later, Nightingale published an annual report setting a revenue target of at least EUR 10 million for the current financial year.

The work will use Alamar Biosciences' NULISAseq™ Neuro 220 Panel, which is designed for neurodegeneration and other brain health conditions. At the Foundation's direction, the dataset goes to UK Biobank and opens to the wider research community in 2027. The aim is to find blood markers that change years before the symptoms of Alzheimer's and Parkinson's appear.

CEO and founder Teemu Suna said the company believes the deal will produce the world's largest brain health-focused proteomics study on a single research cohort.

The contract puts Nightingale's move into proteomics to work

The annual report says Nightingale expanded its offering into proteomics in response to growing interest in multiomics, strengthening its position in the research market. The step came through its November 2025 partnership with Alamar.

The report describes research as a separate business with its own customers and products. It is also where much of the evidence for Nightingale's healthcare business comes from, including measurements of all roughly 500,000 UK Biobank participants. The largest research agreements the report lists for the past financial year were with Aalborg University, at about EUR 2.4 million, and the Moli-sani study, at about EUR 0.7 million.

Stay sharp on Finnish market in just two minutes a day.

The previous day's top signals across Finnish-listed companies: results, deals, board and leadership moves. Fast, factual, no noise.

Delivered from Monday to Friday, first thing.

By signing up, you agree to our Privacy Policy

Stay sharp on Finnish market in just two minutes a day.

The previous day's top signals across Finnish-listed companies: results, deals, board and leadership moves. Fast, factual, no noise.

Delivered from Monday to Friday, first thing.

By signing up, you agree to our Privacy Policy

Revenue follows the samples, and the first read comes in March

Nightingale's revenue for the financial year ended June 2026 was EUR 5.50 million, up from EUR 4.69 million. That fell short of the more than 50% growth the company had targeted. In June, Nightingale warned that a EUR 2.4 million project announced in September 2025 had been delayed for reasons outside its control. As a result, about EUR 2 million of revenue moves into the current financial year. Suna called it "timing, not lost business".

The company recognises revenue over time as samples are analysed. It collects advance payments for most of its services, and the gap between payment and analysis is typically three to six months. The release gives no timeline for analysing the 60,000 samples.

The company expects its liquid funds of EUR 36.8 million to last until the end of the 2027/2028 financial year. The half-year report on 9 March 2027 will be the first chance to see how much of the delayed project and the Fox Foundation contract has turned into revenue towards the EUR 10 million target.

Board Programme

Built for Nordic listed company boards.

The only programme in the Nordics designed specifically for listed-company board work.
Five sessions, one cohort, twenty leaders in one room - Helsinki, 2026.

Board Programme

Built for Nordic listed company boards.

The only programme in the Nordics designed specifically for listed-company board work.
Five sessions, one cohort, twenty leaders in one room - Helsinki, 2026.

Topics

# Topics

Authors

Devdatta Temgire is a data and business analyst at Listeds. He contributes research, data analysis, and pattern detection to the publication’s coverage of Nordic-listed companies, with a focus on board composition, leadership transitions, and financials. He holds an honors degree in artificial intelligence and data science alongside a bachelor’s in computer engineering, and previously worked at KPMG.

Devdatta Temgire is a data and business analyst at Listeds. He contributes research, data analysis, and pattern detection to the publication’s coverage of Nordic-listed companies, with a focus on board composition, leadership transitions, and financials. He holds an honors degree in artificial intelligence and data science alongside a bachelor’s in computer engineering, and previously worked at KPMG.

Authors

Devdatta Temgire is a data and business analyst at Listeds. He contributes research, data analysis, and pattern detection to the publication’s coverage of Nordic-listed companies, with a focus on board composition, leadership transitions, and financials. He holds an honors degree in artificial intelligence and data science alongside a bachelor’s in computer engineering, and previously worked at KPMG.

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

Latest signalsLive feed
Moves trackerLive feed

Investor Event

Listeds Investor Event · Defence

Nordic defence is in a once-in-a-generation growth cycle. Eight listed and pre-IPO companies pitch to 100+ invited investors at Valkoinen Sali, Helsinki

21 September 2026

Latest on Listeds

Monthly Leadership Moves

September's finance seats started filling from inside

Oct 9, 2026

Through August, every incoming chief financial officer at a Helsinki issuer since December 2025 already held the title somewhere else. In September, Vincit promoted from its own controlling team and UPM made WISA's interim finance chief permanent. The lateral market did not close: Tieto and Relais both hired sitting finance chiefs, and Terveystalo is now searching for one.

Listeds had recorded at least ten CFO changes across Nasdaq Helsinki and First North between December 2025 and August 2026, and not one incoming finance chief was taking the job for the first time. Last month's roundup ended on whether September would break that run. It did, at the smaller end of the market.

The month's second signal was structural. Viking Line, Kalmar, Terveystalo and the planned UPM and Sappi graphic paper joint venture each redrew an organization in September and named the people to run it. Board-level change stayed thin, and most of it was nomination-board formation for the 2027 annual general meetings rather than turnover in the boardroom itself.

Vincit and WISA broke the lateral run with internal finance appointments

The Digia and Vincit chain that opened in August closed in September. Vincit named a successor on September 01, and went inside to do it. Paula Kuittinen, Head of Management Accounting and Business Control since March 2026 and before that more than 12 years in finance roles at CGI, most recently she has been the Finance Director, now becoming the CFO on November 1. "It is great to be able to appoint our new CFO from within the company," said chief executive Julius Manni.

On September 18, UPM's board appointed Lasse von Hertzen, previously WISA's interim CFO, its permanent Senior Vice President and Chief Financial Officer, effective when the plywood demerger completes. That finishes a WISA leadership team named in full by the parent's board, with trading expected from November 2.

LapWall took a third route. Tuomo Riihonen's employment ended on September 24, and the next day the company named Tiina Määttä Chief Financial Officer and Legal Officer from October 1. Her record runs through finance and legal advisory roles at Talenom and Greenstep and the chief executive seat at Kymsol Group.

Kempower named Lasse Hatinen on September 9, bringing more than 15 years of finance leadership in listed industrial companies. He joins by March 1, 2027 at the latest, from Metso where he has served as Senior Vice President, Group Controller. Juha Jaatinen, interim since August 13, holds the seat until then.

Larger issuers kept buying finance chiefs who already hold the title

The lateral market remains the default above small cap. Tieto appointed Juuso Pajunen from Terveystalo on September 16, and Terveystalo opened its search the same day. Relais Group appointed Joonas Mäkipeska on September 14 from Technopolis, where he is Chief Financial and Strategy Officer, after CFO roles at Holiday Club Resorts, Sponda and ALD Automotive. Chief executive Christian Gebauer framed the brief as "continued profitable growth, supported by financial discipline, strong cash conversion and investment discipline."

Stora Enso moved the other way on the same theme: on September 17 CFO Niclas Rosenlew was named deputy chief executive to President & CEO Hans Sohlström while keeping the finance role. Tallink appointed Armin Penner as its new CFO on September 8. He has worked for more than six years as CFO and Management Board Member of Circle K Eesti and has also served as CFO of Euroapteek and Ragn-Sells Eesti. 

SSH went outside for its chief executive, Arvo went to its own board

September's two listed-issuer CEO appointments took opposite routes. SSH Communications Security named Lars Bell from Omada, where he was Chief Customer Officer and interim chief executive, effective October 1. The share rose 49.5% in the five sessions to September 7. Bell inherits a business whose second-quarter revenue recovered to EUR 5.7 million, up 6.8%, while EBITDA fell 40.7%, and he starts on the same day as CFO Cristian Arias. The third-quarter report will be the first one a rebuilt executive team owns.

Arvo Sijoitusosuuskunta named Teemu Kokko, a member of its board of directors since 2021, deputy chief executive from December and chief executive from April 1, 2027. The selection ran through a nomination committee drawn from the cooperative's supervisory board, one level above the board Kokko sits on. He inherits first-half operating profit of EUR 8.5 million against EUR 6.5 million a year earlier, most of the step-up traced to an approximately EUR 6.9 million gain on the HANZA exit.

Reorganizations, not departures, produced most management-team changes

The month's largest management-team changes came attached to new structures. Kalmar announced plans on September 3 to simplify its operating model by combining divisions. Terveystalo said on September 4 it will report in four segments from 2027, Healthcare Services, Oral Health, Public Partnerships and Sweden, and named Ville Pesonen senior vice president for oral health. Viking Line renewed its management structure on September 8 and established a Viking Leadership Team. UPM and Sappi nominated Gunnar Eberhardt and Stephen Blyth to lead their planned graphic paper joint venture on September 8, and the wider management team on September 14. 

Technology seats moved alongside. Aspocomp named Ville Raatikainen Chief Engineering and Technology Officer from January 1, 2027, the second outside hire to its team since July, timed to the phased commissioning of its expanded Oulu plant.

Directors moving into executive roles drove September's committee changes

Only one board chair left. Kari Syrjänen resigned as chair of Biohit on September 2. The two committee changes that followed shared a cause: a director taking an executive job. Tulikivi's audit committee chair Niko Haavisto left the board after becoming CFO of Fiskars, and Panu Paappanen became the chairperson on September 14. At Olvi, director Tarmo Noop left the audit committee to run the Estonian subsidiary A. Le Coq on an interim basis, and board chair Nora Hortling replaced him.

September split the finance pipeline by company size

September broke the lateral CFO run, but only at the smaller end of the market: Vincit and WISA filled their finance seats from inside, while Tieto and Relais kept hiring sitting finance chiefs. At chief executive level, Arvo promoted from its own board and SSH went outside. Most management-team changes followed reorganizations rather than departures. On boards, the committee changes came from directors moving into executive roles, and most other activity was nomination-board formation for 2027. With interim finance cover at Kempower and Relais and an open seat at Terveystalo, the next test is whether larger issuers start filling finance seats from within. 

Join our Pulse, Best-of-the-Week, and Weekend newsletters

Join our Pulse, Best-of-the-Week, and Weekend newsletters